Issue Date: April 16, 2012
URL Brings Gout Drug To Takeda
Takeda Pharmaceuticals has agreed to acquire Philadelphia-based URL Pharmaceuticals for $800 million up front plus unspecified performance-based milestone payments. URL, which had $600 million in sales last year, specializes in gout treatment. Its lead product, Colcrys, had 2011 sales of $430 million. Takeda’s lead gout treatment is Uloric, used to lower blood uric acid levels in adults with gout.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society